The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

摘要

Cdc20 mRNA expression is increased in DLBCL and MCL patients and is associated with worse survival in DLBCL patients. , Cdc20 and Cdh1 mRNA expression in DLBCL. Cdc20 ( ) and Cdh1 ( ) gene expression levels of B-cell samples (  = 33), patients with ABC–DLBCL (  = 190), patients with GCB–DLBCL (  = 212) and patients with unclassified DLBCL (  = 67) were obtained from the publicly available microarray datasets and . Mean expression±SD is shown in red. **  p c, Cdc20 and Cdh1 mRNA expression in indolent and aggressive MCL. Cdc20 ( ) and Cdh1 ( ) gene expression levels of patients with indolent (  = 7) and aggressive MCL (  = 15) were obtained from the dataset. Mean expression ± SD is shown in red. *  e, Prognostic value of Cdc20 and Cdh1 mRNA levels in terms of overall survival in DLBCL. The prognostic value of Cdc20 ( ) and Cdh1 ( ) was determined in DLBCL patients receiving R-CHOP treatment from the Lenz cohort (  = 233) using Maxstat analysis (cut-off value used for Cdc20 is 11.679 and for Cdh1 8.319). Data were analysed through genomicscape ( ). – Immunohistochemical analysis of Cdc20 expression in primary DLBCL patient samples. Immunohistochemical analysis of Cdc20 expression in a DLBCL patient. A ×4 and ×40 magnification is shown ( ). Percentage of Cdc20-positive lymphoma cells was counted in 34 DLBCL patients and plotted against the estimated prognosis according to the R-IPI score of the patients ( ). Percentage of Cdc20-positive cells was also plotted against the molecular subtype ( ) and double-expresser status ( ) in 27 DLBCL patients